midas

Acid Ceramidase-IN-1 is a highly effective, orally bioavailable inhibitor of acid ceramidase (AC, ASAH-1) with an IC50 of 0.166 μM and exhibits exceptional brain penetration capabilities in mice.

Acid Ceramidase-IN-2 (compound 1), an acid ceramidase inhibitor, exhibits potentially antiproliferative and cytostatic effects. It is of interest due to the overexpression of human acid ceramidase in prostate cancer cells, suggesting potential anti-tumor efficacy. The hydrolysis of Acid Ceramidase-IN-2 can be inhibited by 3 a-ketoamides: GT85, GT98, and GT99 in vitro [1].

Endoglycoceramidase II (EGCase II), an endo-β-glucosidase, catalyzes the hydrolysis of the β-glycosidic linkage between oligosaccharides and ceramides in glycosphingolipids, releasing the complete glycan from ceramide [1] [2].

Endoglycoceramidase I (EGCase I), a glycosidase frequently utilized in biochemical studies, catalyzes a transglycosylation reaction. This process involves transferring the sugar moiety of GSLs to the primary hydroxyl group of various 1-alkanols [1].

Penicillin amidase (Penicillin acylase) is an enzyme utilized for cleaving the acyl side chains from penicillins. It facilitates the production of 6-aminopenicillanic acid and is also employed in resolving racemic mixtures, peptide synthesis, and the creation of semi-synthetic β-lactam antibiotics [1] [2] [3].

Amidases, belonging to the nitrilase superfamily, catalyze amide hydrolysis to yield carboxylic acid and ammonia. These enzymes feature a conserved AS sequence of about 130 amino acids and are pivotal in essential metabolic processes [1].

Galactosylceramidase plays a role in the lysosomal catabolism of galactosylceramide. It can be utilized in research related to Krabbe disease.